Clinical Trials · NCT00924807
Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
- Phase
- Phase 1/Phase 2
- Recruitment status
- Terminated
- Sponsor
- Beth Israel Medical Center
- Enrollment
- 4
- Start date
- Sep 2008
- Locations
- 1 site, United States
- Primary endpoint
- Determine the Safety and Maximally Tolerated Dose of Sorafenib Administered Concurrently With Radiotherapy in the Treatment of Intermediate- and High-risk Localized Prostate Cancer.